Why the study?
Does antiplatelet therapy reduce recurrent stroke and major vascular events in patients with ischemic stroke or TIA?
Does antiplatelet therapy reduce recurrent stroke and major vascular events in patients with ischemic stroke or TIA?
Antiplatelet therapy is crucial for secondary stroke prevention, but the choice of agent should be individualized based on patient risk profiles, tolerability, and specific clinical scenarios.
May inform individualized antiplatelet selection beyond aspirin for secondary prevention; leaves open prospective RCTs in contemporary cohorts.
The aim of this review is to provide evidence-based recommendations on the secondary prevention of atherothrombotic ischemic stroke. Antiplatelets are the major therapy for the secondary stroke prevention. The most commonly used antiplatelets agents are aspirin, clopidogrel, and extended-release dipyridamole. A lot of progress had been made in last years regarding aspirin resistance and genotyping of clopidogrel metabolism. According to the results of the accomplished studies it is difficult to broadly recommend one antithrombotic agent in favor of the other. Instead, a review of the currently published data suggests the importance of focusing on the individualizing approach in antiplatelet therapy.
No takes yet. Share an insight, caveat, or question.
Shulga et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: